| Calcium-activated chloride channel 1 (CLCA1)127
|
OV-90 cells |
Affects cancer cell regulation |
| Insulin-like growth factor 2 (IMP2) and minichromosome maintenance complex component 2 (MCM2)131
|
HGSC and endometrial tissue |
Modulators of rapid high-grade serous cancer growth |
| Fibronectin and vitronectin133
|
Peritoneal mesothelial cells |
Increased expression promotes cancer cell invasion |
| Chloride intracellular channel protein 1 (CLIC1)134
|
Tissue |
Determined to promote tumorigenesis |
| Histone acetylation130,135
|
Tumor tissue |
Marker for homologous recombination deficiency |
| Phospholinoleate-palmitoleate anhydride (P-MAPA), interleukin 12 (IL-12)137
|
SKOV-3 |
Combination immunotherapy is a plausible treatment strategy |
| Cancer/testis antigen family 45 (CT45)138
|
Tissue |
Found to be a prognostic factor |
| Apolipoprotein E (ApoE), epithelial cell adhesion molecule (EpCAM), plasminogen (PLG), serpin family C member 1 (serpinC1) and complement component 1q (C1q)141
|
Circulating exosomes |
Diagnostic markers of ovarian cancer |
| Vitamin K-dependent protein Z (VKDP) |
Preclinical serum |
Novel, early detection biomarker |
| Phosphopantothenoylcysteine synthetase (PPCS), peripheral myelin protein 2 (PMP2) and tubulin beta class I (TUBB)146
|
Blood, plasma |
Potential markers of cancer plasticity |
| Apolipoprotein IV (ApoA-IV)148
|
Serum |
More reliable biomarker compared to benchmark proteins |
